BR112021025416A2 - Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares - Google Patents

Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares

Info

Publication number
BR112021025416A2
BR112021025416A2 BR112021025416A BR112021025416A BR112021025416A2 BR 112021025416 A2 BR112021025416 A2 BR 112021025416A2 BR 112021025416 A BR112021025416 A BR 112021025416A BR 112021025416 A BR112021025416 A BR 112021025416A BR 112021025416 A2 BR112021025416 A2 BR 112021025416A2
Authority
BR
Brazil
Prior art keywords
prevotella
histicola
melaninogenica
copd
treatment
Prior art date
Application number
BR112021025416A
Other languages
English (en)
Inventor
Veena Taneja
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of BR112021025416A2 publication Critical patent/BR112021025416A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares. a presente invenção refere-se a métodos e materiais relacionados ao tratamento de uma condição pulmonar, tal como doença pulmonar obstrutiva crônica (dpoc), usando uma composição que contém prevotella viva (por exemplo, p. histicola e/ou p. melaninogenica), prevotella morta (ou eliminada) (por exemplo, p. histicola e/ou p. melaninogenica), componentes de prevotella (por exemplo, p. histicola e/ou p. melaninogenica), vesículas (por exemplo, omvs) de prevotella (por exemplo, p. histicola e/ou p. melaninogenica), ou uma combinação dos mesmos. por exemplo, são proporcionados métodos e materiais para usar uma composição que contém prevotella viva (por exemplo, p. histicola e/ou p. melaninogenica), prevotella morta (ou eliminada) (por exemplo, p. histicola e/ou p. melaninogenica), componentes de prevotella (por exemplo, p. histicola e/ou p. melaninogenica), vesículas (por exemplo, omvs) de prevotella (por exemplo, p. histicola e/ou p. melaninogenica), ou uma combinação dos mesmos, para tratar uma condição pulmonar, tal como dpoc.
BR112021025416A 2019-06-17 2020-06-17 Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares BR112021025416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
BR112021025416A2 true BR112021025416A2 (pt) 2022-02-22

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025416A BR112021025416A2 (pt) 2019-06-17 2020-06-17 Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares

Country Status (11)

Country Link
US (1) US20220296657A1 (pt)
EP (1) EP3983067A4 (pt)
JP (1) JP2022537178A (pt)
KR (1) KR20220024466A (pt)
CN (1) CN114340732A (pt)
AU (1) AU2020295393A1 (pt)
BR (1) BR112021025416A2 (pt)
CA (1) CA3143597A1 (pt)
CO (1) CO2022000029A2 (pt)
MX (1) MX2021015711A (pt)
WO (1) WO2020257248A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182707A1 (en) * 2021-02-26 2022-09-01 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
NZ555692A (en) * 2002-07-19 2009-02-28 Abbott Biotech Ltd Treatment of TNF alpha related disorders
EP3255994B1 (en) * 2015-02-03 2020-04-08 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
AU2016319131B2 (en) * 2015-09-09 2022-10-13 Revivicor, Inc. Multi-transgenic pig for xenotransplantation
JP2020533291A (ja) * 2017-09-08 2020-11-19 エヴェロ バイオサイエンシズ，インコーポレーテッド プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）由来の細胞外小胞
EP3886881A2 (en) * 2018-11-30 2021-10-06 Ospedale San Raffaele S.r.l. Bacterial strains for medical uses

Also Published As

Publication number Publication date
WO2020257248A1 (en) 2020-12-24
CO2022000029A2 (es) 2022-04-08
US20220296657A1 (en) 2022-09-22
CA3143597A1 (en) 2020-12-24
AU2020295393A1 (en) 2022-01-06
CN114340732A (zh) 2022-04-12
KR20220024466A (ko) 2022-03-03
MX2021015711A (es) 2022-02-03
JP2022537178A (ja) 2022-08-24
EP3983067A1 (en) 2022-04-20
EP3983067A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
BR112021025416A2 (pt) Preparações de prevotella e tratamento de doença pulmonar obstrutiva crônica (dpoc) e outras condições pulmonares
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112018006448A2 (pt) derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos
BR112018013827A2 (pt) moduladores de 5?-nucleotidase, ecto e uso dos mesmos
PH12020550051A1 (en) Glp-1 compositions and uses thereof
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12018501502A1 (en) Egf(a) analogues with fatty acid substituents
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
BR112017012799A2 (pt) combinações de composto ativo que compreendem um derivado de (tio)carboxamida e composto(s) fungicida(s).
BR112017014545A2 (pt) formulações de oxitocina que contém magnésio e métodos de uso
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
AU2019363725B2 (en) Stable semaglutide compositions and uses thereof
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
PH12020551618A1 (en) Erenumab compositions and uses thereof
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
BR112017027303A2 (pt) domínio variável único de imunoglobulina contra proteína f de rsv